Johnson & Johnson raises 2025 sales forecast by $700m after adding schizophrenia drug to its portfolio
SA’s biggest private hospital group is beefing up its AI and radiology capabilities
The disposal of LMI is expected to be completed in the second half of the 2025 financial year
Mudiwa Gavaza is joined by Ron Whelan, CEO of Discovery Health
Business Day TV spoke to Johann Slabber, founder & CEO of Nexus Pharma
The £1.5bn takeover proposal is below what a US private group has offered
Business Day TV spoke to Mvuyisi Mzukwa, chair of the SA Medical Association
H&H widens offerings to soften blow of impending restrictions on selling copies of Novo Nordisk’s obesity drug
In 2024, Novo invested €4.6bn in life sciences targeting cancer, obesity and neurodegenerative disorders, adding 43 new firms and exiting 27
This is third time that the healthcare conglomerate’s bankruptcy strategy has failed in court
Isomorphic is a spin-off from Alphabet’s AI research subsidiary Google Deepmind
Higher demand for its acute hospitals offset by a decline in occupancy rates for mental health services
Business Day TV speaks with Carl Neethling, CEO of Ascendis
The former pharmaceuticals group reported a 12% year-on-year increase in net asset value to R660m
Africa’s biggest drugmaker warns it has breached standards at one of three sterile units in Gqeberha
Business Day TV speaks to Palesa Mokomele, head of community engagement and communications at DKMS Africa
The Swiss drugmaker is looking to boost its prospects in the weight-loss market
OECD’s BEPS Pillar 2 tax has driven the company’s effective tax rate up to 25%
Business Day Spotlight speaks to Craig Comrie, CEO of Profmed
Performance was affected by constrained consumer spending in the lower living standard measures